Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 ligase to a target protein to facilitate ubiquitination and subsequent degradation of that protein. While the field of targeted degraders is still relatively young, the potential for this modality to become a differentiated and therapeutic reality is strong, such that both academic and pharmaceutical institutions are now entering this interesting area of research. In this article, we describe a broadly applicable process for identifying degrader hits based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) and have generalized the key structural elements associated with degradation activities. Compound 3i is a potent hit (TBK1 DC 50 = 12 nM, D max = 96%) with excellent selectivity against a related kinase IKKε, which was further used as a chemical tool to assess TBK1 as a target in mutant K-Ras cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparable findings in B16 cells were observed using two additional TBK1 inhibitors, MRT67307 32 and GSK8612 33 (Extended Data Fig. 6g-h) and the TBK1-targeted proteolysis targeting chimera (TBK1 PROTAC 3i) 34 (Extended Data Fig. 6i).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [34]
In the citing paper
“It has been shown that a PROTAC’s ability to bind the target protein is not the primary determinant of whether efficient degradation occurs; rather, it has been suggested that formation of the ternary complex is limiting (i.e., the ability of the PROTAC to simultaneously bind both the target protein and the E3 ligase) 20, 22.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [22]
In the citing paper
“Similar positive outcomes could be achieved with PROTACs targeting TANK-binding kinase 1 (TBK1) [92], and ALK, where a clear correlation between efficacy in inhibiting cell proliferation and ALK driver status in different cell lines could be observed [93].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [92]
Citations
Cites
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationCatalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citationStructural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Self-citationSelective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Self-citationOral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
The emerging complexity of protein ubiquitination
Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Self-citation
Cited by
Items 101–200 of 292
Targeting TANK-binding kinase 1 (TBK1) in cancer
Revach, O., Liu, S., & Jenkins, R. W. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1826929 · Cited by 55
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 54
Aminopyrimidines: Recent synthetic procedures and anticancer activities
Filho, É. V., Pinheiro, E. M. C., Pinheiro, S., & Greco, S. J. (2021) · Tetrahedron · doi:10.1016/j.tet.2021.132256 · Cited by 53
Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer
Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 51
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00385-8 · Cited by 51
Self-citationXu, H., Wedn, A. M., Wang, J., Gu, Y., Liu, H., Zhang, J., Lin, Z., Zhou, R., Pang, X., & Cui, Y. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107063 · Cited by 51
Self-citationInhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy
Zhang, M., Zou, Y., Zhou, X., & Zhou, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954129 · Cited by 50
Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
Lefranc, J., Schulze, V., Hillig, R. C., Briem, H., Prinz, F., Mengel, A., Heinrich, T. K., Bálint, J., Rengachari, S., Irlbacher, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01460 · Cited by 49
Song, X., Zhong, H., Qu, X., Yang, L., & Jiang, B. (2021) · MedComm · doi:10.1002/mco2.42 · Cited by 48
Pagett, A. B., & Lloyd‐Jones, G. C. (2019) · Wiley eBooks · doi:10.1002/0471264180.or100.09 · Cited by 48
Chana, C. K., Maisonneuve, P., Posternak, G., Grinberg, N. G. A., Poirson, J., Ona, S. M., Ceccarelli, D. F., Mader, P., St-Cyr, D. J., Pau, V., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00509 · Cited by 47
Protein Tyrosine Phosphatases: Regulators of CD4 T Cells in Inflammatory Bowel Disease
Pike, K. A., & Tremblay, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02504 · Cited by 47
PROTACS: A technology with a gold rush-like atmosphere
Wang, Y., Lan, L., Wang, M., Zhang, J., Gao, Y., Shi, L., & Sun, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115037 · Cited by 47
Towards design of drugs and delivery systems with the Martini coarse-grained model
Kjølbye, L. R., Pereira, G. P., Bartocci, A., Pannuzzo, M., Albani, S., Marchetto, A., Jiménez‐García, B., Martin, J., Rossetti, G., Cecchini, M., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16 · Cited by 46
Inducing Protein Degradation as a Therapeutic Strategy
Crews, C. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01333 · Cited by 46
Self-citationRana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 46
The application of PROTAC in HDAC
Chen, S., Zheng, Y., Liang, B., Yin, Y., Yao, J., Wang, Q., Liu, Y., & Neamati, N. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115746 · Cited by 46
A review on the role of TANK-binding kinase 1 signaling in cancer
Alam, M., Hasan, G. M., & Hassan, M. I. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.06.022 · Cited by 46
Huang, B., Yang, J., & Shen, W. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.344831 · Cited by 45
Valeur, E., & Jimonet, P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00378 · Cited by 43
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 42
TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery
Xiang, S., Song, S., Tang, H., Smaill, J. B., Wang, A., Xie, H., & Lu, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.016 · Cited by 42
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 41
PROTAC Degrader of Estrogen Receptor α Targeting DNA-Binding Domain in Breast Cancer
Zhang, X., Zhang, Z., Xue, X., Fan, T., Tan, C., Liu, F., Tan, Y. C., & Jiang, Y. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00109 · Cited by 40
Qi, Z., Yang, G., Deng, T., Wang, J., Zhou, H., Popov, S. A., Shults, E. E., & Wang, C. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104901 · Cited by 39
Self-citationA comprehensive review of emerging approaches in machine learning for de novo PROTAC design
Gharbi, Y., & Mercado, R. (2024) · Digital Discovery · doi:10.1039/d4dd00177j · Cited by 39
Drewry, D. H., Annor‐Gyamfi, J. K., Wells, C. I., Pickett, J. E., Dederer, V., Preuß, F., Mathea, S., & Axtman, A. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00440 · Cited by 39
Macabuag, N., Esmieu, W., Breccia, P., Jarvis, R. E., Blackaby, W., Lazari, O., Urbonas, L., Eznarriaga, M., Williams, R., Strijbosch, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01149 · Cited by 38
Inducing Protein Degradation as a Therapeutic Strategy
Crews, C. M., Georg, G., & Wang, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00735 · Cited by 37
Self-citationPereira, G. P., Gouzien, C., Souza, P. C. T., & Martin, J. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbaf056 · Cited by 37
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Saleem, R. S. Z., Schwalm, M. P., & Knapp, S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117718 · Cited by 36
Tan, L., & Gray, N. S. (2018) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800293 · Cited by 35
Liu, H., Li, Z., Reindl, T., He, Z., Qiu, X., Golden, R. P., Donovan, K. A., Bailey, A. L., Fischer, E. S., Zhang, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49161-9 · Cited by 35
Rational Prediction of PROTAC-Compatible Protein–Protein Interfaces by Molecular Docking
Pereira, G. P., Jiménez‐García, B., Pellarin, R., Launay, G., Wu, S., Martin, J., & Souza, P. C. T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01154 · Cited by 34
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787 · Cited by 33
Chemical Probes for Understudied Kinases: Challenges and Opportunities
Serafim, R. A. M., Elkins, J. M., Zuercher, W. J., Laufer, S., & Gehringer, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00980 · Cited by 33
Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?
Powell, M., Blaskovich, M. A. T., & Hansford, K. A. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00203 · Cited by 32
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Pravin, N., & Jóźwiak, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116837 · Cited by 32
Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
Yuan, M., Chu, Y., & Duan, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.691093 · Cited by 31
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Riching, K. M., Vasta, J. D., Hughes, S. J., Zoppi, V., Maniaci, C., Testa, A., Urh, M., Ciulli, A., & Daniels, D. L. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100009 · Cited by 30
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative
Zhang, J., Chen, P., Zhu, P., Zheng, P., Wang, T., Wang, L., Xu, C., Zhou, J., & Zhang, H. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103817 · Cited by 29
Ma, X., Wang, X., Chen, F., Zou, W., Ren, J., Xin, L., He, P., Liang, J., Xu, Z., Dong, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00131 · Cited by 29
Targeted protein degradation as an antiviral approach
Chakravarty, A., & Yang, P. L. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105480 · Cited by 29
The size matters? A computational tool to design bivalent ligands
Pérez-Benito, L., Henry, A., Matsoukas, M.-T., Lopez, L., Pulido, D., Royo, M., Cordomí, A., Tresadern, G., & Pardo, L. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty422 · Cited by 28
Sun, J., Gu, M., Peng, L., Guo, J., Chen, P., Wen, Y., Fang, F., Chen, X., Liu, T., Chen, Y., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c11003 · Cited by 27
Roles of Cullin-RING Ubiquitin Ligases in Cardiovascular Diseases
Diaz, S., Wang, K., Sjögren, B., & Liu, X. (2022) · Biomolecules · doi:10.3390/biom12030416 · Cited by 27
Chemical regulation of the cGAS-STING pathway
Zhang, Q., Chen, C., Xia, B., & Xu, P. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102170 · Cited by 27
Identification of PDE6D as a potential target of sorafenib via PROTAC technologyPreprint
Li, Y., Meng, Q., Wang, P., Liu, X., Fu, Q., Xie, Y., Zhou, Y., Qi, X., & Huang, N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.06.079947 · Cited by 26
Arthur, R., Valle‐Argos, B., Steele, A. J., & Packham, G. K. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00009 · Cited by 25
Costanzo, A. D., Gaudio, N. D., Conte, L., & Altucci, L. (2020) · Cancers · doi:10.3390/cancers12071898 · Cited by 24
Exploiting E3 ligases for lung cancer therapy: The promise of DCAF-PROTACs
Hussain, M. S., Eltaib, L., Rana, A. J., Maqbool, M., Ashique, S., Alanazi, M. N., Khan, Y., & Agrawal, M. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156001 · Cited by 24
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 22
Alam, M., Ansari, M. M., Noor, S., Mohammad, T., Hasan, G. M., Kazim, S. N., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.157 · Cited by 22
Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications
Negi, A., Kesari, K. K., & Voisin‐Chiret, A. S. (2022) · Applied Sciences · doi:10.3390/app12199674 · Cited by 22
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
Tomaselli, D., Mautone, N., Mai, A., & Rotili, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112750 · Cited by 21
Cheng, S., Feng, Y., Li, W., Liu, T., Lv, X., Tong, X., Xi, G., Ye, X., & Li, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116629 · Cited by 21
Lin, W., Li, Y., Yang, L., & Chen, T. (2020) · ACS Omega · doi:10.1021/acsomega.0c05221 · Cited by 20
Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor
Kato, J., Korenaga, S., & Iwakura, M. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129083 · Cited by 20
Negi, A., Kieffer, C., & Voisin‐Chiret, A. S. (2022) · ChemistrySelect · doi:10.1002/slct.202200981 · Cited by 20
Nóvoa, L., Trulli, L., Parra, A., & Tortosa, M. (2021) · Angewandte Chemie · doi:10.1002/ange.202101445 · Cited by 20
Liu, R., Qian, M., & Cui, Y. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155665 · Cited by 19
Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
Kounde, C. S., & Tate, E. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01542 · Cited by 19
Cai, G., Zhang, X., Jiao, J., Du, W., & Yan, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090750 · Cited by 19
Amberchan, G., Snelling, R. A., Moya, E., Landi, M., Lutz, K., Gatihi, R., & Singaram, B. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c03062 · Cited by 19
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Lu, X., Jin, J., Wu, Y., Liu, X., Liang, X., Lin, J., Sun, Q., Qin, J., Zhang, W., & Luan, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21993 · Cited by 17
Design and pharmaceutical applications of proteolysis-targeting chimeric molecules
Liang, Y., Nandakumar, K. S., & Cheng, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114211 · Cited by 17
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Lindner, S., Steinebach, C., Kehm, H., Mangold, M., Gütschow, M., & Krönke, J. (2019) · Journal of Visualized Experiments · doi:10.3791/59472 · Cited by 16
Recent progress in small molecule TBK1 inhibitors: a patent review (2015– 2020)
Thomson, D. W., & Bergamini, G. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1904893 · Cited by 16
Chimera induced protein degradation: PROTACs and beyond
Yin, L., & Hu, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112494 · Cited by 15
Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs
Gong, L., Cui, D., Xiong, X., & Zhao, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_19 · Cited by 15
Proteolysis-targeting Chimeras for Targeting Protein for Degradation
Qi, J., & Zhang, G. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0557 · Cited by 15
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras
Bhole, R. P., Patil, S., Kapare, H. S., Chikhale, R. V., & Gurav, S. S. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266309968240621072550 · Cited by 15
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 15
Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
Torres‐Ayuso, P., & Brognard, J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.121.000306 · Cited by 15
Kim, H. J., Kim, H., Kim, S., Roh, J., Yun, J. H., & Kim, C. (2025) · Autophagy · doi:10.1080/15548627.2025.2481661 · Cited by 14
Expression and purification of functional recombinant CUL2•RBX1 from E. coli
Diaz, S., Li, L., Wang, K., & Liu, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-90770-x · Cited by 14
Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Mukhamejanova, Z., Tong, Y., Xiang, Q., Xu, F., & Pang, J. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312112412 · Cited by 13
Giardina, S. F., Valdambrini, E., Singh, P. K., Bacolod, M. D., Babu-Karunakaran, G., Peel, M. R., Warren, J. D., & Barany, F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02097 · Cited by 13
Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7)
Ji, W., Du, G., Jiang, J., Lu, W., Mills, C. E., Yuan, L., Jiang, F., He, Z., Bradshaw, G. A., Chung, M., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116613 · Cited by 13
Si, R., Zhu, H., Wang, J., Zhang, Q., Li, Y., Pan, X., & Zhang, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106439 · Cited by 12
Self-citationG protein-coupled receptor–targeted proteolysis-targeting chimeras in cancer therapeutics
Saca, V. R., Huber, T., & Sakmar, T. P. (2024) · Molecular Pharmacology · doi:10.1016/j.molpha.2024.100013 · Cited by 11
Lai, S., Wang, B., Sun, K., Li, F., Liu, Q., Yu, X., Jiang, L., & Wang, L. (2024) · Molecules · doi:10.3390/molecules29081845 · Cited by 11
BBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma
Liao, C., Hu, L., Jia, L., Zhou, J. R., Wang, T., Kim, K., Zhong, H., Yao, H., Dong, L., Guo, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56955-y · Cited by 11
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
Progress on Small-Molecule Proteolysis-Targeting Chimeras
Huang, W., Wang, B., Zhang, Z., Zhang, C., Zeng, S., & Shen, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0161 · Cited by 10
PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?
Cromm, P. M., Crews, C. M., & Weinmann, H. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00001 · Cited by 9
Self-citationProteolysis targeting chimera of BI-2536 induces potent dual degradation of PLK1 and BET proteins
Song, S., Yang, W., & Tai, W. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118087 · Cited by 9
Tomoshige, S., & Ishikawa, M. (2020) · Angewandte Chemie · doi:10.1002/ange.202004746 · Cited by 8
The ubiquitin code of RAS proteins: Decoding its role in cancer progression
Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 8
Self-citationGuo, J., Tang, H., Zhao, W., Li, Y., Song, S., Feng, F., Huang, S., Wang, X., Zhou, Y., Pei, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00722 · Cited by 8
Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy
Ohoka, N. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00113 · Cited by 8
Soto-Martínez, D. M., Clements, G. D., Díaz, J. E., BECHER, J., Reynolds, R. C., Ochsenbauer, C., & Snowden, T. S. (2024) · RSC Advances · doi:10.1039/d4ra01974a · Cited by 8
PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
Du, M., Liu, T., Wang, W., Fan, S., Tian, M., Du, Q., Wang, Z., Li, X., Liu, X., Xia, Q., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100332 · Cited by 7
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 7
Khan, M. Z. I., Nazli, A., Pan, Y., & Chen, J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220803112409 · Cited by 7
STING antagonists, synthesized via Povarov–Doebner type multicomponent reaction
Ong, W. W. S., Dayal, N., Chaudhuri, R., Lamptey, J., & Sintim, H. O. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00061c · Cited by 7
Computational Modeling of PROTAC Ternary Complexes and Linker Design
Miller, S. A., Andrianov, G. V., Mischley, V., Wharton, K. A., Chen, J. J., & Karanicolas, J. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch5 · Cited by 7
Metadata
- Authors
- Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., Siu, K., Neklesa, T. K., Winkler, J. D., Coleman, K. G., & Crews, C. M.
- Affiliations
- Arvinas (United States) (US)
- Yale University (US)
- Corresponding author
- Crew, Andrew P.
- Crews, Craig M.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-07-10
- Volume
- 61
- Issue
- 2
- Pages
- 583-598
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2735419424
- Cited by
- 257
- References
- 29
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 25 · 2023: 22 · 2022: 36 · 2021: 42 · 2020: 43 · 2019: 30 · 2018: 21 · 2017: 4
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R35CA197589)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, TBK1, targeted protein degradation, VHL, serine/threonine kinase inhibitors, IKKε, bifunctional molecules
- MeSH terms
- Cell Line, Fluorescence Polarization, Humans, Mutation, Genes, ras, Structure-Activity Relationship, Molecular Structure, Protein Serine-Threonine Kinases, RNA Interference, Cell Proliferation, I-kappa B Kinase, Von Hippel-Lindau Tumor Suppressor Protein, Proteolysis, Chemistry Techniques, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.